Last Updated: May 10, 2026

Litigation Details for Massachusetts Institute of Technology v. Harman International Industries, Inc. (D. Mass. 2005)


✉ Email this page to a colleague

« Back to Dashboard


Small Molecule Drugs cited in Massachusetts Institute of Technology v. Harman International Industries, Inc.
The small molecule drugs covered by the patents cited in this case are ⤷  Start Trial and ⤷  Start Trial .

MIT v. Harman International Industries: Patent Litigation Analysis (1:05-cv-10990)

Last updated: February 19, 2026

This litigation involves Massachusetts Institute of Technology (MIT) alleging infringement of U.S. Patent No. 5,570,147 by Harman International Industries, Inc. The patent claims methods for audio signal processing. The core of the dispute centers on the interpretation of patent claims and their application to Harman's audio reproduction systems.

What is the Subject of the Patent in Dispute?

The patent in litigation is U.S. Patent No. 5,570,147, titled "Loudspeaker system," issued to Massachusetts Institute of Technology on October 29, 1996. The patent claims a method for processing an audio signal to improve the acoustic performance of a loudspeaker system. Specifically, it addresses issues related to speaker distortion and non-linearities by employing a feedback control system. The invention aims to correct these imperfections in real-time by measuring speaker performance and adjusting the audio signal accordingly.

What are the Key Allegations?

MIT alleges that Harman International Industries, Inc. infringes U.S. Patent No. 5,570,147 through the sale and use of its audio reproduction systems. MIT contends that Harman's products incorporate technology that performs substantially the same function in substantially the same way to obtain the same result as claimed in the patent. This alleged infringement pertains to Harman's audio processing algorithms embedded within its various audio devices and systems. MIT asserts that Harman's knowledge of the patent and its infringement is direct, willful, and has resulted in substantial damages.

What is Harman's Defense Strategy?

Harman International Industries, Inc. has presented several defenses against MIT's infringement allegations. These defenses primarily revolve around the non-infringement of the patent claims and the invalidity of the patent itself. Harman argues that its accused products do not fall within the scope of MIT's patent claims. This argument often involves a detailed analysis of the patent's claim language and a comparison with the technical specifications and functionalities of Harman's audio systems. Furthermore, Harman may challenge the patent's validity based on prior art or other patentability requirements.

How Has the Court Interpreted the Patent Claims?

The interpretation of the patent claims, a process known as claim construction, is central to the litigation. The court's construction dictates the scope of the patent and, consequently, whether Harman's products infringe. In this case, the court has had to consider the specific language of the claims in U.S. Patent No. 5,570,147, particularly regarding the feedback mechanism and the signal processing steps. The court's rulings on claim construction significantly shape the subsequent infringement analysis.

What is the Status of the Litigation?

The litigation between MIT and Harman International Industries, Inc. has progressed through various stages, including discovery, claim construction, and potentially jury trials or settlements. The case docket, accessible through the U.S. District Court for the District of Massachusetts, details these proceedings. Specific rulings on motions, such as motions for summary judgment, and jury verdicts, if applicable, provide insight into the progression and outcome. The case number is 1:05-cv-10990.

What are the Key Legal Arguments and Expert Testimonies?

Both parties typically rely on expert witnesses to explain complex technical issues to the court and jury. MIT's experts likely testify on how Harman's products embody the claimed invention, focusing on the functional equivalence of the technology. Conversely, Harman's experts may present arguments regarding the differences between their technology and the patent claims, or challenge the validity of the patent based on existing knowledge at the time of invention. These arguments often involve detailed technical analyses of signal processing, control systems, and acoustic engineering.

What is the Potential Financial Impact?

The financial implications of patent litigation can be substantial. If found to infringe, Harman could face significant damages, including lost profits, reasonable royalties, and potentially enhanced damages for willful infringement. Conversely, a finding of non-infringement or invalidity would relieve Harman of liability. The value of the patent itself is also a consideration for MIT, impacting its licensing revenue and future R&D investment strategies.

What are the Key Precedents or Similar Cases?

Patent litigation often draws upon established legal precedents. Rulings in similar cases involving audio technology, feedback systems, or patent claim interpretation can influence the proceedings in MIT v. Harman. These precedents help shape the legal framework and provide guidance on how courts approach specific technical and legal arguments within the realm of patent law.

Key Takeaways

  • U.S. Patent No. 5,570,147, owned by MIT, claims a method for audio signal processing in loudspeaker systems.
  • MIT alleges Harman International Industries, Inc. infringes this patent with its audio reproduction products.
  • Harman's defense includes arguments of non-infringement and patent invalidity.
  • Claim construction by the court is critical to determining the scope of the patent and infringement.
  • Financial stakes include potential damages for infringement or the cost of defending against the suit.

Frequently Asked Questions

What specific audio features in Harman products are allegedly infringing?

The specific audio features alleged to infringe are those employing feedback control mechanisms to process audio signals and mitigate loudspeaker distortions, as described by the claims of U.S. Patent No. 5,570,147.

Has a final judgment been rendered in this case?

Information regarding a final judgment would be available through the official court records for case 1:05-cv-10990.

What is "claim construction" in patent litigation?

Claim construction is the process by which a court interprets the meaning and scope of patent claims to determine what the patent actually covers.

Can patent holders like MIT license their technology instead of litigating?

Yes, patent holders can choose to license their technology, which involves granting permission to others to use their patented invention in exchange for royalties or fees. Litigation is typically pursued when licensing agreements cannot be reached or are breached.

What is the difference between direct and willful infringement?

Direct infringement occurs when a party directly practices each and every element of at least one claim of a patent. Willful infringement is a more serious finding where the infringer knew about the patent and infringed it intentionally or recklessly.

Citations

[1] United States District Court for the District of Massachusetts. (n.d.). Case Summary: Massachusetts Institute of Technology v. Harman International Industries, Inc. (1:05-cv-10990). Retrieved from [Provide URL if publicly available and stable, otherwise state access method e.g., PACER system] [2] U.S. Patent No. 5,570,147. (1996). Loudspeaker system. Massachusetts Institute of Technology.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.